Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1994 Feb;8(1):137-45.
doi: 10.1007/BF00877102.

Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs

I Nakae  1 , L Quan, K Hashimoto, Y Sugimoto, T Tsutamoto, M Kinoshita
Affiliations
Comparative Study

Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs

I Nakae et al. Cardiovasc Drugs Ther. 1994 Feb.

Abstract

Nicorandil possesses hybrid properties as a nitrate and a potassium (K) channel opener. We have previously reported that large coronary arteries responded to nicorandil at low plasma concentrations, while dilatation of small coronary arteries only occurred at higher plasma concentrations (above 200 ng/ml) in chronically instrumented dogs. In this study we examined the effects of intravenous nicorandil on epicardial coronary artery diameter (CoD) and coronary blood flow (CBF) in the absence and presence of glibenclamide, a K+ channel blocker, as well as the effects of nitroglycerin and cromakalim as reference drugs. The increase in CBF induced by nicorandil and cromakalim was significantly suppressed by glibenclamide. However, the increase in CoD induced by nicorandil and nitroglycerin was not suppressed by glibenclamide. These findings suggest that nicorandil-induced dilatation of the large coronary arteries was related to its nitrate action, while nicorandil-induced dilatation of the small coronary arteries was closely related to its effect as a K+ channel opener. In addition, the former response to nicorandil occurred at low concentrations, while the latter occurred at higher concentrations.

PubMed Disclaimer

References

    1. J Cardiovasc Pharmacol. 1991 Jun;17(6):903-12 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1991 Jan;343(1):76-82 - PubMed
    1. J Biol Chem. 1987 Nov 25;262(33):15840-4 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):258-63 - PubMed
    1. Cardiovasc Drugs Ther. 1990 Aug;4(4):1119-26 - PubMed

Publication types